These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 8767348)
1. Ca2+ sensitization in idiopathic dilated human myocardium. Differential in vitro effects of (+)-(5-methyl-6-phenyl)-1,3,5,6-tetrahydro-3,6-methano-1,5-benzodiazoci ne-2,4-dione, a novel purely Ca2+sensitizing agent, and (+)-5-(1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydroquinolin-6-yl)-6-meth yl-3, 6-dihydro-2H-1,3,4-thiadiazin-2-one on skinned fibres and isolated ventricular strips. Herzig JW; Chiesi M; Depersin H; Grüninger S; Hasenfuss G; Kubalek R; Leutert T; Pieske B; Pioch K; Wenk P; Holubarsch C Arzneimittelforschung; 1996 Jun; 46(6):586-93. PubMed ID: 8767348 [TBL] [Abstract][Full Text] [Related]
2. 5-Methyl-6-phenyl-1,3,5,6-tetrahydro-3,6-methano-1,5-benzodiazocine-2,4-dione (BA 41899): representative of a novel class of purely calcium-sensitizing agents. Herold P; Herzig JW; Wenk P; Leutert T; Zbinden P; Fuhrer W; Stutz S; Schenker K; Meier M; Rihs G J Med Chem; 1995 Jul; 38(15):2946-54. PubMed ID: 7636855 [TBL] [Abstract][Full Text] [Related]
3. CGP-48506 increases contractility of ventricular myocytes and myofilaments by effects on actin-myosin reaction. Wolska BM; Kitada Y; Palmiter KA; Westfall MV; Johnson MD; Solaro RJ Am J Physiol; 1996 Jan; 270(1 Pt 2):H24-32. PubMed ID: 8769730 [TBL] [Abstract][Full Text] [Related]
4. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers. Lues I; Beier N; Jonas R; Klockow M; Haeusler G J Cardiovasc Pharmacol; 1993 Jun; 21(6):883-92. PubMed ID: 7687712 [TBL] [Abstract][Full Text] [Related]
5. A novel positive inotropic substance enhances contractility without increasing the Ca2+ transient in rat myocardium. Ferroni C; Hano O; Ventura C; Lakatta EG; Klockow M; Spurgeon H; Capogrossi MC J Mol Cell Cardiol; 1991 Mar; 23(3):325-31. PubMed ID: 1880816 [TBL] [Abstract][Full Text] [Related]
6. Effects of the Ca2+ sensitizers EMD 57033 and CGP 48506 on myocardial contractility and Ca2+ transients in human ventricular and atrial myocardium. Brixius K; Reicke S; Reuter H; Schwinger RH Z Kardiol; 2002 Apr; 91(4):312-8. PubMed ID: 12063703 [TBL] [Abstract][Full Text] [Related]
7. EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium. Uhlmann R; Schwinger RH; Lues I; Erdmann E Basic Res Cardiol; 1995; 90(5):365-71. PubMed ID: 8585857 [TBL] [Abstract][Full Text] [Related]
8. The novel inotropic agent CGP 48506 alters force primarily by Ca(2+)-independent mechanisms in porcine skinned trabeculae. Palmer S; Di Bello S; Davenport SL; Herzig JW Cardiovasc Res; 1996 Aug; 32(2):411-21. PubMed ID: 8796129 [TBL] [Abstract][Full Text] [Related]
9. (-)-Enantiomer EMD 57439 antagonizes the Ca2+ sensitizing effect of (+)-enantiomer EMD 57033 on diastolic function but not on systolic function in rabbit ventricular cardiomyocytes. Sugawara H; Endoh M Jpn J Pharmacol; 1999 May; 80(1):55-65. PubMed ID: 10446757 [TBL] [Abstract][Full Text] [Related]
10. Different effect of the Ca(2+) sensitizers EMD 57033 and CGP 48506 on cross-bridge cycling in human myocardium. Brixius K; Mehlhorn U; Bloch W; Schwinger RH J Pharmacol Exp Ther; 2000 Dec; 295(3):1284-90. PubMed ID: 11082466 [TBL] [Abstract][Full Text] [Related]
11. Novel diazinone derivatives separate myofilament Ca2+ sensitization and phosphodiesterase III inhibitory effects in guinea pig myocardium. Ventura C; Miller R; Wolf HP; Beier N; Jonas R; Klockow M; Lues I; Hano O; Spurgeon HA; Lakatta EG Circ Res; 1992 Jun; 70(6):1081-90. PubMed ID: 1533576 [TBL] [Abstract][Full Text] [Related]
12. The novel cardiotonic agent EMD 53 998 is a potent "calcium sensitizer". Beier N; Harting J; Jonas R; Klockow M; Lues I; Haeusler G J Cardiovasc Pharmacol; 1991 Jul; 18(1):17-27. PubMed ID: 1719287 [TBL] [Abstract][Full Text] [Related]
13. In vivo evidence of positive inotropism of EMD 57033 through calcium sensitization. Haeusler G; Jonas R; Minck KO; Schliep HJ; Schelling P; Weygandt H; Lues I J Cardiovasc Pharmacol; 1997 May; 29(5):647-55. PubMed ID: 9213208 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart. Orstavik O; Ata SH; Riise J; Dahl CP; Andersen GØ; Levy FO; Skomedal T; Osnes JB; Qvigstad E Br J Pharmacol; 2014 Dec; 171(23):5169-81. PubMed ID: 24547784 [TBL] [Abstract][Full Text] [Related]
15. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure? Zimmermann N; Boknik P; Gams E; Herzig JW; Neumann J; Scholz H Eur J Cardiothorac Surg; 1998 Jul; 14(1):70-5. PubMed ID: 9726618 [TBL] [Abstract][Full Text] [Related]
16. The effects of EMD 57033 on rigor tension in porcine skinned cardiac trabecula. Palmer S; Di Bello S; Herzig JW Eur J Pharmacol; 1995 Dec; 294(1):83-90. PubMed ID: 8788419 [TBL] [Abstract][Full Text] [Related]
18. Enantiomeric dissection of the effects of the inotropic agent, EMD 53998, in single cardiac myocytes. Gambassi G; Capogrossi MC; Klockow M; Lakatta EG Am J Physiol; 1993 Mar; 264(3 Pt 2):H728-38. PubMed ID: 8384421 [TBL] [Abstract][Full Text] [Related]
19. Positive inotropic effects of calcium sensitizers on normal and failing cardiac myocytes. Tsutsui H; Kinugawa S; Ide T; Hayashidani S; Suematsu N; Satoh S; Nakamura R; Egashira K; Takeshita A J Cardiovasc Pharmacol; 2001 Jan; 37(1):16-24. PubMed ID: 11152370 [TBL] [Abstract][Full Text] [Related]